An Overview of a Practice-Changing Trial With mFOLFIRINOX in Pancreatic Cancer
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX (mFOLFIRINOX) regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
While gemcitabine has been the standard of care since 2008, a mFOLFIRINOX regimen of fluorouracil (5-FU), oxaliplatin, leucovorin, and irinotecan was developed in France to show superiority. While it was superior to gemcitabine in metastatic disease, it was still too toxic for use in the adjuvant setting.
Bolus 5-FU is suppressed in the mFOLFIRINOX regimen and instead continuous infusion of 5-FU is used with the other agents. In this trial, mFOLFIRINOX was compared to gemcitabine in patients 3 to 12 weeks after surgery for 6 months.
See more information on thispractice-changing trial in pancreatic cancer and the results
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
